Skip to main content

news

 

Clifford Chance has advised the Hong Kong-listed SciClone Pharmaceuticals on an offer to take it private by healthcare-focused private equity firm GL Capital, with Slaughter and May acting for the buyer’s financial adviser, Capital Corporation Hong Kong Securities (CICC).

The transaction was implemented via a scheme of arrangement, which allows for a cash consideration of up to an approximate total of $1.13 billion.

Founded in 2010, GL Capital is an investment firm focusing on buyouts and growth opportunities in China’s healthcare industry.

SciClone is engaged in developing and commercialising a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas, including oncology and severe infection. The company was listed in Hong Kong in March 2021.

The Clifford Chance team was led by partners Christine Xu and Tommy Tam.

 Meanwhile, the Slaughter team was headed by partner Bonita Yu.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Nishimura guides Goldman Sachs on $530mln Japan take-private deal

by Nimitt Dixit |

Japanese Big Four firm Nishimura & Asahi has advised global investment bank Goldman Sachs on its acquisition and privatisation via management buyout of Nihon Housing, a building and real estate management company, for $530 million.

Deals

SAM, CAM, Hogan Lovells guide Acme Solar’s $343mln India IPO

by Nimitt Dixit |

Shardul Amarchand Mangaldas & Co has advised Acme Solar, one of India's largest renewable energy independent power producers, on its $343 million initial public offering.

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.